Sana Biotechnology, Inc. (SANA) Form 8-K — May 11, 2026
Sana Biotechnology, Inc. reported its first quarter 2026 financial results, with a cash position of $101.1 million and a pro forma cash position of $128.9 million, including a $25.0 million equity investment from Mayo Clinic. The company also announced a strategic collaboration with Mayo Clinic to advance the development of SC451, a gene-modified, stem cell-derived pancreatic islet cell therapy for type 1 diabetes. Sana shared positive clinical results from an investigator-sponsored trial of UP421, an allogeneic primary islet cell therapy, which showed ongoing survival and function of pancreatic beta cells in a patient with type 1 diabetes without the use of immunosuppression.
Key figures
- Eps
- -0.17
- Eps Beat
- 0
- Revenue
- 0
- Net Income
- -47,210
- Total Debt
- 254,353
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 373,593
- Cash Position
- 101,136
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 276,856
- Pro Forma Cash Position
- 128,900
- Equity Investment From Mayo Clinic
- 25,000
Price after filing
Close on the filing date to close N calendar days later (from $3.56). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.